Page last updated: 2024-11-06

miglustat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Miglustat is a synthetic, oral, iminosugar analog of N-butyldeoxynojirimycin (NB-DNJ). It is an inhibitor of glucosylceramide synthase (GCS), an enzyme involved in the synthesis of glucosylceramide (GlcCer), a major component of cell membranes. Miglustat has been shown to reduce the accumulation of GlcCer in various tissues, including the brain, liver, and spleen. This reduction in GlcCer levels is believed to be responsible for the therapeutic effects of miglustat in several lysosomal storage disorders (LSDs), such as Gaucher disease, Niemann-Pick disease type C, and Fabry disease. Miglustat has also been investigated for its potential therapeutic effects in other conditions, including cancer, diabetes, and Alzheimer's disease. The importance of miglustat lies in its ability to modulate the synthesis of GlcCer, a key component of cell membranes, leading to a decrease in the accumulation of this lipid in various tissues. This therapeutic effect is particularly beneficial in LSDs, where the accumulation of GlcCer is a major cause of disease pathology. The study of miglustat aims to understand its mechanism of action, optimize its therapeutic efficacy, and explore its potential applications in various diseases.'

miglustat: a glucosylceramide synthase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID51634
CHEMBL ID1029
CHEBI ID50381
SCHEMBL ID246893
MeSH IDM0461235

Synonyms (88)

Synonym
AB00489939-10
ogt-918
zavesca
vevesca
n-bu-dnj
sc-48334
brazaves
n-butyl-deoxynojirimycin
n-(n-butyl)-1,5-dideoxy-1,5-imino-d-glucitol
CHEBI:50381 ,
miglustatum
zavesca (tn)
miglustat (jan/usan/inn)
D05032
brazaves (tn)
n-butyl dnj
miglustat [usan]
ogt 918
d-glucitol, 1,5-(butylimino)-1,5-dideoxy-
3,4,5-piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2r-(2alpha,3beta,4alpha,5beta))-
3,4,5-piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2r,3r,4r,5s)-
1,5-dideoxy-1,5-n-butylimino-d-glucitol
n-butylmoranoline
n-butyldeoxynojirimycin
sc 48334
n-butyl-dnj
72599-27-0
nb-dnj
miglustat
(2r,3r,4r,5s)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
n-butyldeoxynojirimycin, film (dried in situ)
nbv ,
DB00419
n-(n-butyl)deoxynojirimycin
n-butyl deoxynojirimycin
n-butyl-1-deoxynojirimycin
butyldeoxynojirimycin
budnj
chembl1029 ,
bdbm18355
HMS2090N20
NCGC00024452-03
n-(n-butyl)deoxy-nojirimycin
adn3s497az ,
unii-adn3s497az
miglustat [usan:inn:ban]
sc48334
dtxcid4025618
tox21_110830
dtxsid6045618 ,
cas-72599-27-0
n-butyldeoxynojirimycin.hcl
miglustat [vandf]
miglustat [orange book]
miglustat [jan]
1,5-(butylimino)-1,5 dideoxy,d-glucitol
miglustat [mi]
miglustat [ema epar]
miglustat [who-dd]
miglustat [inn]
miglustat [mart.]
gtpl4841
SCHEMBL246893
HY-17020
NCGC00024452-04
tox21_110830_1
W-203639
mfcd00272581
AKOS028109118
sr-01000000043
SR-01000000043-2
Q425911
n-(n-butyl)-1-deoxynojirimycin min. 99%
134282-77-2
n-butyldeoxynojirimycin;nb-dnj;ogt918
UQRORFVVSGFNRO-UTINFBMNSA-N
72599-27-0 (free base)
A850985
1,5-(butylimino)-1,5-dideoxy-d-glucitol(2r,3r,4r,5s)-1-butyl-2-(hydroxymethyl)-3,4,5-piperidinetriol
P16976
ogt918
ogt918n-butyldeoxynojirimycin
3,4,5-piperidinetriol, 1-butyl-2-(hydroxymethyl)-,(2r-(2alpha,3beta,4alpha,5beta))-
a16ax06
1,5-(butylimino)-1,5-dideoxy-d-glucitol
yargesa
miglustat (mart.)
Z2379810058

Research Excerpts

Overview

Miglustat (Zavesca) is a reversible inhibitor of the enzyme glucosylceramide synthase, which catalyses the first step in the biosynthesis of most glycosphingolipids. Miglustat (OGT 918) is an iminosugar recently introduced in therapeutic as potential alternative therapy in disorders found in Tay-Sachs, Gaucher or Niemann-Pick diseases.

ExcerptReferenceRelevance
"Miglustat is an oral medication for treatment of lysosomal storage diseases such as Gaucher disease type I and Niemann Pick disease type C. "( Long term differential consequences of miglustat therapy on intestinal disaccharidases.
Amiri, M; Naim, HY, 2014
)
2.11
"Miglustat (Zavesca(®)) is an oral treatment for type 1 Gaucher disease and Niemann-Pick disease type C. "( Stability of refrigerated miglustat after preparation in InOrpha(®) flavored suspending excipient for compounding of oral solutions and suspensions.
Ambühl, M; Bandilla, D; Riahi, S; Stichler, J, 2015
)
2.16
"Miglustat (Zavesca) is a reversible inhibitor of the enzyme glucosylceramide synthase, which catalyses the first step in the biosynthesis of most glycosphingolipids."( Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: a case report in Brazil.
Cordeiro, ML; Liberalesso, PB; Löhr, A; Raskin, S; Santos, ML; Telles, DS; Vieira, SC, 2008
)
1.3
"Miglustat (OGT 918) is an iminosugar recently introduced in therapeutic as potential alternative therapy in disorders found in several diseases such as Tay-Sachs, Gaucher or Niemann-Pick diseases. "( Rapid quantification of miglustat in human plasma and cerebrospinal fluid by liquid chromatography coupled with tandem mass spectrometry.
Cohen, S; Coste, S; Guffon-Fouilhoux, N; Guillaumont, M; Guitton, J; Manchon, M, 2009
)
2.1
"Miglustat was shown to be a safe drug, with mild to moderate diarrhea, as an age-dependent DRAE, which was controlled by dietary modification."( Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
Banwell, B; Clarke, JT; Dingemanse, J; Maegawa, GH; Morgan, CP; Tifft, CJ; van Giersbergen, PL; Yang, S, 2009
)
1.33
"Miglustat (Zavesca) is an orally-available substrate reduction therapy (SRT) for treatment of mild-to-moderate type 1 Gaucher disease (GD1) in adult patients unsuitable for enzyme replacement therapy (ERT). "( Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Bembi, B; Hollak, CE; Hughes, D; Schwierin, B; van Schaik, IN, 2009
)
3.24
"Miglustat (Zavesca) is a reversible inhibitor of glucosylceramide synthase, which catalyses the first committed step in the synthesis of glucose-based glycolipids."( Miglustat therapy in juvenile Sandhoff disease.
Berg, JE; Tallaksen, CM, 2009
)
2.52
"Miglustat is an oral medication that has approved indication for type I Gaucher disease and Niemann pick disease type C. "( Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of α-glucosidases, but not β-galactosidases.
Amiri, M; Naim, HY, 2012
)
3.26
"Miglustat is an inhibitor of glucosylceramide synthase, a key enzyme in GSL synthesis."( Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses, C, 2003
)
1.04
"Miglustat is an N-alkylated imino sugar that acts against a number of enzymes involved in processing glycoconjugates, including the ceramide-specific glucosyltransferase, which catalyzes the initial committed step in glycosphingolipid synthesis."( Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
Lachmann, RH, 2006
)
2.5
"Miglustat (Zavesca) is a reversible inhibitor of glucosylceramide synthase, which catalyses the first step in the glucosylceramide biosynthetic pathway, and is approved for therapy in patients with type 1 Gaucher disease. "( The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat.
Clozel, M; Morand, O; Treiber, A, 2007
)
2

Effects

Miglustat has been shown to stabilize disease progression in children, juveniles and adults with Niemann-Pick disease type C (NP-C) It has pharmacokinetic properties that allow it to cross the blood-brain barrier. Preclinical data suggest that it may benefit neuronopathic lysosomal storage diseas.

ExcerptReferenceRelevance
"Miglustat has an acceptable safety profile."( Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study.
Bin-Dorel, S; Decullier, E; Fouilhoux, A; Guffon, N; Guitton, J; Paillet, C, 2011
)
1.45
"Miglustat has been indicated for the treatment of Niemann-Pick disease type C (NP-C) since 2009. "( Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study.
Garver, WS; Giugliani, R; Héron, B; Imrie, J; Jahnova, H; Meaney, FJ; Moneuse, P; Morand, O; Nadjar, Y; Patterson, MC; Rosenberg, D; Schwierin, B; Vanier, MT, 2020
)
2.23
"Miglustat has previously been reported to halt or improve early dysphagia and cognitive symptoms."( Characterization of Dysphagia and Longitudinal Changes in Swallowing Function in Adults with Niemann-Pick Disease Type C Treated with Miglustat.
Keage, M; Lewis, C; Schubiger, D; Velakoulis, D; Vogel, AP; Walterfang, M; Watanabe, M, 2021
)
1.55
"Miglustat has pharmacokinetic properties that allow it to cross the blood-brain barrier, thus making it a potential therapeutic agent for treating neurological symptoms in NPC patients."( Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: a case report in Brazil.
Cordeiro, ML; Liberalesso, PB; Löhr, A; Raskin, S; Santos, ML; Telles, DS; Vieira, SC, 2008
)
1.3
"Miglustat has not been evaluated in children with GD1, and is not used during pregnancy and breast-feeding."( Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Bembi, B; Hollak, CE; Hughes, D; Schwierin, B; van Schaik, IN, 2009
)
2.52
"Miglustat has been shown to stabilize disease progression in children, juveniles and adults with Niemann-Pick disease type C (NP-C), a rare genetic disorder characterized by progressive neurological deterioration. "( Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study.
Bembi, B; Giorgino, R; Hwu, WL; Korenke, GC; Luzy, C; Marquardt, T; Mengel, E; Patterson, MC; Pineda, M; Rohrbach, M; Sedel, F; Walterfang, M; Wraith, JE, 2009
)
3.24
"Miglustat has pharmacokinetic properties that allow it to cross the blood-brain barrier, and preclinical data suggest that it may benefit neuronopathic lysosomal storage diseases."( Miglustat therapy in juvenile Sandhoff disease.
Berg, JE; Tallaksen, CM, 2009
)
2.52
"Miglustat has an acceptable safety profile."( Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study.
Bin-Dorel, S; Decullier, E; Fouilhoux, A; Guffon, N; Guitton, J; Paillet, C, 2011
)
1.45
"Miglustat has demonstrated efficacy to slow down the neurological impairment in NP-C patients assessed by the modified disability scale."( Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
Gordo, MM; Marfa, MP; Pérez-Poyato, MS, 2012
)
1.1

Actions

ExcerptReferenceRelevance
"The miglustat-treated mice produce morphologically abnormal spermatozoa that lack acrosomes and are poorly motile."( The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study.
Bone, W; Boomkamp, S; Fritsch, M; Gottwald, U; Leifke, E; Platt, FM; van der Spoel, AC; Voigtmann, U; Walden, CM, 2007
)
1.08

Treatment

Miglustat is a small imino sugar that reversibly inhibits glucosylceramide synthase. Treatment with miglustat according to dose recommendations for patients with Niemann-Pick disease was well tolerated with manageable toxicities.

ExcerptReferenceRelevance
"Miglustat treatment significantly decreased (adj p < 0.0001) CSF UCHL1 levels by 30% (95% CI 17-40%)."( Elevated cerebrospinal fluid ubiquitin C-terminal hydrolase-L1 levels correlate with phenotypic severity and therapeutic response in Niemann-Pick disease, type C1.
Berry-Kravis, E; Cawley, NX; Cologna, SM; Dang Do, A; Farhat, NM; Giddens, S; Liu, F; Luke, RA; Mohamed, HO; Porter, FD; Scott, KEJ, 2023
)
1.63
"Miglustat-treated and untreated patients overall and within sub-groups according to age-at-neurological-onset, that is, early infantile-onset (<2 years), late infantile-onset (2 to <6 years), juvenile-onset (6 to <15 years), and adolescent/adult-onset (≥15 years) were analysed and compared."( Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study.
Garver, WS; Giugliani, R; Héron, B; Imrie, J; Jahnova, H; Meaney, FJ; Moneuse, P; Morand, O; Nadjar, Y; Patterson, MC; Rosenberg, D; Schwierin, B; Vanier, MT, 2020
)
1.5
"Miglustat treatment might improve or stabilize neurological manifestations but there is still limited data on the long-term efficacy."( Long-term therapy with miglustat and cognitive decline in the adult form of Niemann-Pick disease type C: a case report.
De Rosa, A; Dubbioso, R; Esposito, M; Iodice, R; Manganelli, F; Ruggiero, L; Saccà, F; Santoro, L; Spina, E; Topa, A; Tozza, S, 2018
)
1.51
"Miglustat treatment was associated with a reduced rate of disability score worsening in infantile and juvenile patients, both in agreement with increased age at last contact."( Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease Type C: an international, multicenter, retrospective chart review.
Insua, JL; Juríčková, K; Karimzadeh, P; Kolb, SA; Kolnikova, M; Malinova, V; Pineda, M; Velten, C, 2019
)
1.5
"Miglustat treatment in NPC1 patients slightly decreased IL-3, IL-10 and IL-13 CSF levels; however, further studies are needed to establish a strong effect of miglustat on inflammation markers."( Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1.
Blank, PS; Cluzeau, CV; Cologna, SM; Dail, MK; Lieberman, AP; Porter, FD; Siebel, S; Toth, CL; Wassif, CA; Yanjanin, NM, 2014
)
1.12
"Miglustat treatment was then interrupted with worsening of some neurological signs (memory defects, slowing of thought processes) and skin lesions."( Effects of miglustat treatment in a patient affected by an atypical form of Tangier disease.
Bembi, B; Calandra, S; Dardis, A; De Maglio, G; Di Muzio, A; Maruotti, V; Pizzolitto, S; Platt, F; Rabacchi, C; Sechi, A; Zampieri, S; Zanoni, P, 2014
)
1.51
"Miglustat treatment was not shown to lead to measurable benefits in this cohort of patients with late-onset Tay-Sachs disease. "( Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.
Gianutsos, J; Kolodny, EH; Luzy, C; Pastores, GM; Shapiro, BE, 2009
)
3.24
"Miglustat treatment was not associated with any improvement/stabilization in behavior problems in patients with mucopolysaccharidosis type III. "( Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study.
Bin-Dorel, S; Decullier, E; Fouilhoux, A; Guffon, N; Guitton, J; Paillet, C, 2011
)
2.17
"The miglustat-treated mice produce morphologically abnormal spermatozoa that lack acrosomes and are poorly motile."( The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study.
Bone, W; Boomkamp, S; Fritsch, M; Gottwald, U; Leifke, E; Platt, FM; van der Spoel, AC; Voigtmann, U; Walden, CM, 2007
)
1.08
"A miglustat-based treatment of CF patients may thus have a beneficial effect both on Cl- and Na+ transports."( Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells.
Becq, F; Bot, AG; De Jonge, HR; Noël, S; Wilke, M, 2008
)
1.14
"Treatment with miglustat was not cost-effective when compared with symptomatic therapy and was associated with negative values of net monetary benefit regardless of the onset of neurological manifestations (- 110,447,627.00 ± 701,614.00 RSD, - 343,871,695.00 ± 2,577,441.00 RSD, - 1,397,908,502.00 ± 23,084,235.00 RSD and - 2,953,680,879.00 ± 33,297,412.00 RSD) for early infantile, late infantile, juvenile and adolescent cohorts, respectively)."( Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C.
Gutić, M; Janković, SM; Milosavljević, MN, 2022
)
1.39
"Treatment with miglustat according to dose recommendations for patients with Niemann-Pick disease was well tolerated with manageable toxicities."( Glucosylceramide Synthase Inhibitors Induce Ceramide Accumulation and Sensitize H3K27 Mutant Diffuse Midline Glioma to Irradiation.
Alt, F; Beck, O; Brockmann, MA; El Malki, K; Faber, J; Frauenknecht, KBM; Ottenhausen, M; Paret, C; Russo, A; Sandhoff, R; Sommer, C; Ustjanzew, A; Wehling, P; Wilzius, C; Wingerter, A; Zahnreich, S, 2023
)
1.25
"Treatment with Miglustat at the dose of 600 mg/day was started at the age of 10, 17 and 28 years; age at last evaluation was 21, 20 and 38 respectively."( The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression.
Caciotti, A; Deodato, F; Dionisi-Vici, C; Donati, MA; Morrone, A; Procopio, E; Rampazzo, A; Scarpa, M; Taurisano, R, 2017
)
1.04
"Treatment with miglustat, a small imino sugar that reversibly inhibits glucosylceramide synthase, which is necessary for glycosphingolipid synthesis, has been shown to benefit patients with NPC disease."( Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C.
Bryan, C; Crooks, A; Ding, W; Dingemanse, J; O'Donnell, P; Prociuk, M; Sikora, T; Stein, VM; Vanier, MT; Vite, CH; Walkley, SU, 2012
)
2.16
"Treatment with miglustat was initiated in patient 1 (EI form) at onset of delayed speech."( Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
Gordo, MM; Marfa, MP; Pérez-Poyato, MS, 2012
)
0.72

Toxicity

118 (96%) of 123 patients experienced at least one treatment-emergent adverse event during the study. Gastrointestinal disturbances such as diarrhea and flatulence are the most frequent adverse effects associated with miglustat therapy in type 1 Gaucher disease (GD1) and Niemann-Pick disease type C (NP-C)

ExcerptReferenceRelevance
" Among infantile GM2g patients, the major drug-related adverse events (DRAEs) were abdominal discomfort and flatulence."( Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
Banwell, B; Clarke, JT; Dingemanse, J; Maegawa, GH; Morgan, CP; Tifft, CJ; van Giersbergen, PL; Yang, S, 2009
)
0.61
"Gastrointestinal (GI) disturbances such as diarrhea and flatulence are the most frequent adverse effects associated with miglustat therapy in type 1 Gaucher disease (GD1) and Niemann-Pick disease type C (NP-C), and the most common recorded reason for stopping treatment during clinical trials and in clinical practice settings."( A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat.
Amato, D; Chadha-Boreham, H; Marquardt, T; Morand, O; Remenova, T; Tsurutani, S, 2015
)
0.82
" 118 (96%) of 123 patients experienced at least one treatment-emergent adverse event during the study; the incidence was similar between the cipaglucosidase alfa plus miglustat group (n=81 [95%]) and the alglucosidase alfa plus placebo group (n=37 [97%])."( Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Bratkovic, D; Byrne, BJ; Castelli, J; Díaz-Manera, J; Goldman, M; Jiang, H; Kishnani, PS; Kuchipudi, S; Laforêt, P; Mozaffar, T; Roberts, M; Schoser, B; Sitaraman, S; Toscano, A; van der Ploeg, AT, 2021
)
1.07

Pharmacokinetics

Miglustat was successfully applied to the pharmacokinetic assessment of miglustat during treatment of cystic fibrosis.

ExcerptReferenceRelevance
" The present report describes the pharmacokinetic profile of miglustat in the rat with a focus on tissue distribution."( The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat.
Clozel, M; Morand, O; Treiber, A, 2007
)
0.8
"0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food."( Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase.
Dingemanse, J; van Giersbergen, PL, 2007
)
0.59
" It was successfully applied to the pharmacokinetic assessment of miglustat during treatment of patients with cystic fibrosis."( Validated LC-MS/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic study.
Dingemanse, J; Spieker, E; Wagner-Redeker, W, 2012
)
0.83

Bioavailability

ExcerptReferenceRelevance
"The in vitro fate of an ester prodrug, glycovir, was studied to determine if the species differences in the bioavailability of pharmacologically active SC-48334 observed after glycovir administration and not observed after SC-48334 administration is due to species differences in ester hydrolysis rate or species differences in absorption of the prodrug itself, and to determine the site(s) of ester hydrolysis which contributes most to species differences in the bioavailability of SC-48334 if any."( Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.
Cook, CS; Karabatsos, PJ; Karim, A; Schoenhard, GL, 1995
)
0.29
" After SC-48334 administration, SC-48334 was rapidly and similarly well absorbed in all species."( Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.
Cook, CS; Karabatsos, PJ; Karim, A; Schoenhard, GL, 1995
)
0.29
"The species differences in bioavailability of SC-48334 with the prodrug were due to species differences in hydrolysis rates of the prodrug in small intestinal mucosa."( Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.
Cook, CS; Karabatsos, PJ; Karim, A; Schoenhard, GL, 1995
)
0.29
" This has allowed the successful measurement of imino sugars in animal tissues and will be useful for understanding the factors involved in compound bioavailability and in the design of novel therapeutics."( High-performance cation-exchange chromatography and pulsed amperometric detection for the separation, detection, and quantitation of N-alkylated imino sugars in biological samples.
Adam, A; Butters, TD; Dwek, RA; Mellor, HR; Platt, FM, 2000
)
0.31
" Miglustat was well absorbed and exhibited an oral bioavailability of 40-60%."( The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat.
Clozel, M; Morand, O; Treiber, A, 2007
)
1.47
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Dosing was begun at 8 mg/kg/day and subsequent doses were 16, 32, 48, and 64 mg/kg/day."( The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
Fischl, M; Karim, A; Kessler, H; Merigan, T; Pottage, J; Powderly, W; Richman, D; Sherman, J; Smith, S; Tierney, M, 1995
)
0.29
" During the extension, dosage was increased to 100 mg TID in patients in one center to improve the response."( Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
Aerts, J; Elstein, D; Heitner, R; Weely, Sv; Zimran, A,
)
0.13
" A second drug, N-butyldeoxyglactonojirimycin, looks very promising for treating storage diseases with neurological involvement as high systemic dosing is achievable without any side-effects."( Substrate reduction therapy in mouse models of the glycosphingolipidoses.
Andersson, U; Butters, TD; Dwek, RA; Heare, T; Jeyakumar, M; Platt, FM, 2003
)
0.32
" There is uncertainty as to whether an increase in the dosage of ERT has a beneficial effect."( Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.
Amato, D; Piran, S, 2010
)
0.36
" Four weeks of dosing resulted in decreased plasma triglycerides and reduced hepatic fat deposition."( Discovery and characterization of an inhibitor of glucosylceramide synthase.
Aay, N; Aoyama, R; Arcalas, A; Bentzien, F; Cancilla, B; Chan, V; Du, H; Finn, P; Galan, A; Hanel, A; Harrison, A; Kearney, P; Koltun, ES; Lamb, P; Larson, CJ; Mohan, R; Nachtigall, J; Nuss, J; Ogilvie, K; Plonowski, A; Qian, F; Richards, S; Rosen, J; Tam, D; Wang, T; Won, KA; Yakes, M; Zhang, J; Zhang, W, 2012
)
0.38
" He had received enzyme replacement therapy from the age of 18 months, and concomitant miglustat treatment was commenced, with dosing according to body surface area uptitrated over 1 month with dietary modifications when he reached the age of 30 months."( Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo, F; Concolino, D; Falvo, F; Grisolia, M; Moricca, MT; Sestito, S, 2017
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitorAn EC 2.4.1.* (hexosyltransferase) inhibitor that interferes with the activity of ceramide glucosyltransferase (EC 2.4.1.80).
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
piperidines
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency13.00320.000714.592883.7951AID1259369; AID1259392
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency21.87610.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sucrase-isomaltase Mus musculus (house mouse)IC50 (µMol)1.05000.40000.75001.5000AID1467928; AID553255
Trehalase Sus scrofa (pig)IC50 (µMol)36.00002.50002.50002.5000AID711095
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)5.55000.04003.46529.0000AID104668; AID466668
Ceramide glucosyltransferaseMus musculus (house mouse)IC50 (µMol)40.96670.20001.46674.0000AID386382; AID553252; AID652571
Lysosomal acid glucosylceramidaseHomo sapiens (human)IC50 (µMol)259.00000.03002.35898.8000AID1166038; AID1467931; AID1467932; AID1596603; AID1797728; AID1884450; AID350169; AID553253; AID711099
Lysosomal acid glucosylceramidaseHomo sapiens (human)Ki116.00000.02101.52886.3000AID1797728
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)22.00000.00011.753610.0000AID626355
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)52.73330.06002.28897.8000AID1467933; AID437995; AID466672
Lysosomal alpha-glucosidaseHomo sapiens (human)Ki0.20000.05901.75307.3000AID1819245
Sucrase-isomaltase, intestinalHomo sapiens (human)IC50 (µMol)0.50000.04902.72947.8000AID466667
Sucrase-isomaltase, intestinalRattus norvegicus (Norway rat)IC50 (µMol)18.11140.04001.848310.0000AID208985; AID241705; AID241706; AID241803; AID711102; AID711103; AID91639
Protein-lysine 6-oxidaseHomo sapiens (human)IC50 (µMol)5.00000.01001.19705.0000AID1797728
Protein-lysine 6-oxidaseHomo sapiens (human)Ki116.00000.30000.30000.3000AID1797728
Glycogen debranching enzymeHomo sapiens (human)IC50 (µMol)10.00008.40009.514310.0000AID466673
Lysosomal alpha-glucosidaseMus musculus (house mouse)IC50 (µMol)9.00004.00007.00009.0000AID553257
Lactase-phlorizin hydrolase Rattus norvegicus (Norway rat)IC50 (µMol)637.00000.12002.98674.4000AID711098; AID99232
Ceramide glucosyltransferaseHomo sapiens (human)IC50 (µMol)29.75000.09000.13250.2000AID1166037; AID466666; AID626355; AID699203
Non-lysosomal glucosylceramidaseMus musculus (house mouse)IC50 (µMol)11.52000.14000.14000.1400AID386381; AID386382
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)IC50 (µMol)3.70000.08002.50619.8500AID1467940; AID711104
Non-lysosomal glucosylceramidaseHomo sapiens (human)IC50 (µMol)25.89060.00030.08970.3000AID1166039; AID1467931; AID1596605; AID437994; AID466671; AID553254; AID700852
Putative alpha-glucosidaseOryza sativa Japonica Group (Japanese rice)IC50 (µMol)0.42000.03000.16670.4200AID240826
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (146)

Processvia Protein(s)Taxonomy
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
mitochondrion organizationLysosomal acid glucosylceramidaseHomo sapiens (human)
neuron projection developmentLysosomal acid glucosylceramidaseHomo sapiens (human)
glucosylceramide catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
autophagyLysosomal acid glucosylceramidaseHomo sapiens (human)
lysosome organizationLysosomal acid glucosylceramidaseHomo sapiens (human)
cholesterol metabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
determination of adult lifespanLysosomal acid glucosylceramidaseHomo sapiens (human)
cellular response to starvationLysosomal acid glucosylceramidaseHomo sapiens (human)
response to pHLysosomal acid glucosylceramidaseHomo sapiens (human)
microglia differentiationLysosomal acid glucosylceramidaseHomo sapiens (human)
regulation of macroautophagyLysosomal acid glucosylceramidaseHomo sapiens (human)
antigen processing and presentationLysosomal acid glucosylceramidaseHomo sapiens (human)
lipid storageLysosomal acid glucosylceramidaseHomo sapiens (human)
cerebellar Purkinje cell layer formationLysosomal acid glucosylceramidaseHomo sapiens (human)
pyramidal neuron differentiationLysosomal acid glucosylceramidaseHomo sapiens (human)
respiratory electron transport chainLysosomal acid glucosylceramidaseHomo sapiens (human)
termination of signal transductionLysosomal acid glucosylceramidaseHomo sapiens (human)
lipid glycosylationLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of protein-containing complex assemblyLysosomal acid glucosylceramidaseHomo sapiens (human)
regulation of TOR signalingLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of interleukin-6 productionLysosomal acid glucosylceramidaseHomo sapiens (human)
T cell differentiation in thymusLysosomal acid glucosylceramidaseHomo sapiens (human)
response to testosteroneLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of protein dephosphorylationLysosomal acid glucosylceramidaseHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of protein-containing complex disassemblyLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of MAP kinase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of neuron apoptotic processLysosomal acid glucosylceramidaseHomo sapiens (human)
response to estrogenLysosomal acid glucosylceramidaseHomo sapiens (human)
sphingosine biosynthetic processLysosomal acid glucosylceramidaseHomo sapiens (human)
ceramide biosynthetic processLysosomal acid glucosylceramidaseHomo sapiens (human)
cell maturationLysosomal acid glucosylceramidaseHomo sapiens (human)
brain morphogenesisLysosomal acid glucosylceramidaseHomo sapiens (human)
homeostasis of number of cellsLysosomal acid glucosylceramidaseHomo sapiens (human)
negative regulation of inflammatory responseLysosomal acid glucosylceramidaseHomo sapiens (human)
neuromuscular processLysosomal acid glucosylceramidaseHomo sapiens (human)
neuron apoptotic processLysosomal acid glucosylceramidaseHomo sapiens (human)
establishment of skin barrierLysosomal acid glucosylceramidaseHomo sapiens (human)
microglial cell proliferationLysosomal acid glucosylceramidaseHomo sapiens (human)
motor behaviorLysosomal acid glucosylceramidaseHomo sapiens (human)
cellular response to tumor necrosis factorLysosomal acid glucosylceramidaseHomo sapiens (human)
hematopoietic stem cell proliferationLysosomal acid glucosylceramidaseHomo sapiens (human)
response to dexamethasoneLysosomal acid glucosylceramidaseHomo sapiens (human)
lymphocyte migrationLysosomal acid glucosylceramidaseHomo sapiens (human)
response to thyroid hormoneLysosomal acid glucosylceramidaseHomo sapiens (human)
beta-glucoside catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of protein lipidationLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of neuronal action potentialLysosomal acid glucosylceramidaseHomo sapiens (human)
positive regulation of autophagy of mitochondrion in response to mitochondrial depolarizationLysosomal acid glucosylceramidaseHomo sapiens (human)
autophagosome organizationLysosomal acid glucosylceramidaseHomo sapiens (human)
regulation of lysosomal protein catabolic processLysosomal acid glucosylceramidaseHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lactose catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
glycosylceramide catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
quercetin catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
cellobiose catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose catabolic processSucrase-isomaltase, intestinalHomo sapiens (human)
polysaccharide digestionSucrase-isomaltase, intestinalHomo sapiens (human)
osteoblast differentiationProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of protein phosphorylationProtein-lysine 6-oxidaseHomo sapiens (human)
heart developmentProtein-lysine 6-oxidaseHomo sapiens (human)
response to xenobiotic stimulusProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of gene expressionProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of striated muscle tissue developmentProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
peptidyl-lysine oxidationProtein-lysine 6-oxidaseHomo sapiens (human)
bone mineralizationProtein-lysine 6-oxidaseHomo sapiens (human)
lung developmentProtein-lysine 6-oxidaseHomo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
ascending aorta developmentProtein-lysine 6-oxidaseHomo sapiens (human)
descending aorta developmentProtein-lysine 6-oxidaseHomo sapiens (human)
protein modification processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of apoptotic processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of megakaryocyte differentiationProtein-lysine 6-oxidaseHomo sapiens (human)
muscle cell cellular homeostasisProtein-lysine 6-oxidaseHomo sapiens (human)
elastic fiber assemblyProtein-lysine 6-oxidaseHomo sapiens (human)
blood vessel morphogenesisProtein-lysine 6-oxidaseHomo sapiens (human)
response to steroid hormoneProtein-lysine 6-oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProtein-lysine 6-oxidaseHomo sapiens (human)
muscle cell developmentProtein-lysine 6-oxidaseHomo sapiens (human)
cell chemotaxisProtein-lysine 6-oxidaseHomo sapiens (human)
connective tissue developmentProtein-lysine 6-oxidaseHomo sapiens (human)
DNA biosynthetic processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of bone developmentProtein-lysine 6-oxidaseHomo sapiens (human)
cellular response to chemokineProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of platelet-derived growth factor receptor-beta signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
collagen fibril organizationProtein-lysine 6-oxidaseHomo sapiens (human)
glycogen biosynthetic processGlycogen debranching enzymeHomo sapiens (human)
glycogen catabolic processGlycogen debranching enzymeHomo sapiens (human)
response to nutrientGlycogen debranching enzymeHomo sapiens (human)
response to glucocorticoidGlycogen debranching enzymeHomo sapiens (human)
protein lipidationCeramide glucosyltransferaseHomo sapiens (human)
glucosylceramide biosynthetic processCeramide glucosyltransferaseHomo sapiens (human)
glycosphingolipid biosynthetic processCeramide glucosyltransferaseHomo sapiens (human)
epidermis developmentCeramide glucosyltransferaseHomo sapiens (human)
regulation of signal transductionCeramide glucosyltransferaseHomo sapiens (human)
cell differentiationCeramide glucosyltransferaseHomo sapiens (human)
keratinocyte differentiationCeramide glucosyltransferaseHomo sapiens (human)
leptin-mediated signaling pathwayCeramide glucosyltransferaseHomo sapiens (human)
neuron developmentCeramide glucosyltransferaseHomo sapiens (human)
establishment of skin barrierCeramide glucosyltransferaseHomo sapiens (human)
intestinal lipid absorptionCeramide glucosyltransferaseHomo sapiens (human)
cornified envelope assemblyCeramide glucosyltransferaseHomo sapiens (human)
carbohydrate metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramide catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
cholesterol metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
bile acid metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycoside catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system neuron developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
lipid glycosylationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of actin filament polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of microtubule polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycosphingolipid catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of membrane lipid distributionNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (57)

Processvia Protein(s)Taxonomy
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
galactosylceramidase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
glucosylceramidase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
signaling receptor bindingLysosomal acid glucosylceramidaseHomo sapiens (human)
scavenger receptor bindingLysosomal acid glucosylceramidaseHomo sapiens (human)
protein bindingLysosomal acid glucosylceramidaseHomo sapiens (human)
glucosyltransferase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
steryl-beta-glucosidase activityLysosomal acid glucosylceramidaseHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
lactase activityLactase-phlorizin hydrolaseHomo sapiens (human)
galactosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
glucosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
beta-glucosidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
glycosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
protein homodimerization activityLactase-phlorizin hydrolaseHomo sapiens (human)
cellobiose glucosidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
phlorizin hydrolase activityLactase-phlorizin hydrolaseHomo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
oligo-1,6-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
sucrose alpha-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein bindingSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate bindingSucrase-isomaltase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein-lysine 6-oxidase activityProtein-lysine 6-oxidaseHomo sapiens (human)
copper ion bindingProtein-lysine 6-oxidaseHomo sapiens (human)
protein bindingProtein-lysine 6-oxidaseHomo sapiens (human)
collagen bindingProtein-lysine 6-oxidaseHomo sapiens (human)
small molecule bindingProtein-lysine 6-oxidaseHomo sapiens (human)
molecular adaptor activityProtein-lysine 6-oxidaseHomo sapiens (human)
glycogen debranching enzyme activityGlycogen debranching enzymeHomo sapiens (human)
4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
amylo-alpha-1,6-glucosidase activityGlycogen debranching enzymeHomo sapiens (human)
protein bindingGlycogen debranching enzymeHomo sapiens (human)
polysaccharide bindingGlycogen debranching enzymeHomo sapiens (human)
polyubiquitin modification-dependent protein bindingGlycogen debranching enzymeHomo sapiens (human)
beta-maltose 4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
protein bindingCeramide glucosyltransferaseHomo sapiens (human)
ceramide glucosyltransferase activityCeramide glucosyltransferaseHomo sapiens (human)
dihydroceramide glucosyltransferase activityCeramide glucosyltransferaseHomo sapiens (human)
galactosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosyltransferase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
steryl-beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
lysosomeLysosomal acid glucosylceramidaseHomo sapiens (human)
lysosomal membraneLysosomal acid glucosylceramidaseHomo sapiens (human)
endoplasmic reticulumLysosomal acid glucosylceramidaseHomo sapiens (human)
Golgi apparatusLysosomal acid glucosylceramidaseHomo sapiens (human)
trans-Golgi networkLysosomal acid glucosylceramidaseHomo sapiens (human)
lysosomal lumenLysosomal acid glucosylceramidaseHomo sapiens (human)
extracellular exosomeLysosomal acid glucosylceramidaseHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneLactase-phlorizin hydrolaseHomo sapiens (human)
external side of apical plasma membraneLactase-phlorizin hydrolaseHomo sapiens (human)
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
Golgi apparatusSucrase-isomaltase, intestinalHomo sapiens (human)
plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
brush borderSucrase-isomaltase, intestinalHomo sapiens (human)
apical plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular exosomeSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular regionProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular spaceProtein-lysine 6-oxidaseHomo sapiens (human)
collagen trimerProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular spaceProtein-lysine 6-oxidaseHomo sapiens (human)
collagen-containing extracellular matrixProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular regionGlycogen debranching enzymeHomo sapiens (human)
nucleusGlycogen debranching enzymeHomo sapiens (human)
cytoplasmGlycogen debranching enzymeHomo sapiens (human)
cytosolGlycogen debranching enzymeHomo sapiens (human)
inclusion bodyGlycogen debranching enzymeHomo sapiens (human)
sarcoplasmic reticulumGlycogen debranching enzymeHomo sapiens (human)
secretory granule lumenGlycogen debranching enzymeHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen debranching enzymeHomo sapiens (human)
isoamylase complexGlycogen debranching enzymeHomo sapiens (human)
Golgi membraneCeramide glucosyltransferaseHomo sapiens (human)
membraneCeramide glucosyltransferaseHomo sapiens (human)
Golgi membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
endoplasmic reticulum membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
smooth endoplasmic reticulumNon-lysosomal glucosylceramidaseHomo sapiens (human)
cytosolNon-lysosomal glucosylceramidaseHomo sapiens (human)
plasma membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (226)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1819245Inhibition of human GAA using 4-methylumbelliferyl-alpha-D-glucopyranoside as substrate preincubated for 45 min followed by substrate addition and measured after 30 min by fluorescence spectrophotometer analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
5-
AID1596611Induction of apoptosis in human CuFi1 cells incubated for 48 hrs by Muse Annexin V based cell counter assay2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID1467918Inhibition of Pyrococcus furiosus beta-glucosidase assessed as residual activity at 1 mM using 4 Np-beta-Glc as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID386375Increase in glucosylceramide level in GBA2 deficient C57BL/6-129S1 mouse testes at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID36809Inhibition of lysosomal Alpha-Glucosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1467921Inhibition of recombinant human GBA1 assessed as residual activity at 1 mM2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID99232Inhibition of Glycosidases (lactase)in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID35369Inhibition of lysosomal Alpha-mannosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1467923Inhibition of Thermotoga maritima alpha-galactosidase assessed as residual activity at 1 mM using 4 Np-alpha-Gal as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID1467916Inhibition of recombinant human GAA assessed as residual activity at 1 mM using 4-Np-alpha-Glc as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID1467926Inhibition of beta-galactosidase derived from human HL60 cells assessed as residual activity at 1 mM using 4-MU-Gal as substrate after 30 mins by fluorescence assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID1467924Inhibition of recombinant human alpha-gal A assessed as residual activity at 1 mM using 4 Np-alpha-Gal as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID466672Inhibition of lysosomal alpha-glucosidase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID731622Induction of wild type human beta glucosidase activity expressed in monkey COS7 cells at 10 uM relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID243797Inhibitory activity against beta-Glucosidase from sweet almond at 1000 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID652572Inhibition of recombinant glucosylceramidase 1 using 4-methylumbelliferyl-B-glucoside as substrate by fluorimetric analysis2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.
AID711099Inhibition of human beta-glucocerebrosidase2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID386385Inhibition of conduritol beta-epoxide-sensitive glucosylceramidase in C57BL/6 mouse liver membrane assessed as enzyme activity2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID710955Inhibition of bovine liver beta-galactosidase at 1000 uM2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID386372Increase in glucosylceramide level in C57BL/6 mouse testes administered with chow at 15 mg/kg/day after 3 to 12 months2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID579825Inhibition of rat liver alpha-glucosidase 2 assessed as conversion of Glc2Man7GlcNAc2 to Man7GlcNAc2 at 100 uM after 1.25 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID626355Inhibition of GCS assessed as amount of UDP-glucose consumed during enzyme-catalyzed reaction2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Discovery of a new class of glucosylceramide synthase inhibitors.
AID466667Inhibition of sucrase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1467915Inhibition of wild type C57BL/6 mouse small intestinal sucrase/isomaltase assessed as residual activity at 1 mM using sucrose as substrate after 30 mins2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID350170Cytotoxicity against human HL60 cells assessed as dead cells at 100 uM after 3 days by propidium iodide staining based flow cytometry2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
AID1596606Inhibition of NLGase in human SH-SY5Y cells at 1 nM to 1 mM using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay relative to control2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID466670Inhibition of GBA1 by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1467928Inhibition of wild type C57BL/6 mouse small intestinal sucrase/isomaltase using sucrose as substrate after 30 mins2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID1166037Inhibition of glucosylceramide synthase (unknown origin) assessed as catabolism of NBD-glucosylceramide2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.
AID386374Increase in very long and polyunsaturated glucosylceramide level in C57BL/6 mouse testes at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID386392Effect on spermatogenesis in MA/My mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID386369Increase in glucosylceramide level in C57BL/6 mouse liver administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1895994Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 to 5 days by Cell titer-glo luminescent assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity.
AID482227Inhibition of beta-glucocerebrosidase in human A549 cells at 10 uM after 35 mins by fluorescence-coupled HPLC analysis2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease.
AID711102Inhibition of rat intestinal sucrase using sucrose as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID386370Increase in glucosylceramide level in C57BL/6 mouse brain at 1200 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID652571Inhibition of glucosylceramide synthase in mouse RAW cells preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence scanner2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.
AID466674Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as reduction in plasma glycosphingolipids at 100 mg/kg/day for 4 weeks2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID386387Effect on spermatogenesis in C57BL/10 mouse assessed as morphological changes in spermatozoa at 15 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID386390Effect on spermatogenesis in BALB/c mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID210969Inhibition of Glycosidases (trehalase)in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1467939Allosteric enhancement of GAA p.L552P/p.L552P mutant activity in pompe disease patient derived fibroblasts assessed as increase in levels of mature 76kDa isoform at 20 uM in presence of recombinant human GAA by Western blot method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID241705Inhibition of rat intestinal maltase using disaccharide2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID437993Inhibition of human GBA12009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.
AID1467930Inhibition of rice alpha-glucosidase using 4-Np-alpha-Glc as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID437996Inhibition of rice alpha glucosidase2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.
AID711096Inhibition of rat intestinal trehalase2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386396Effect on spermatogenesis in C3H mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID437999Inhibition of sweet almond beta glucosidase2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID466668Inhibition of maltase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID386395Effect on spermatogenesis in C57BL/6-129S1 mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1467936Allosteric enhancement of GAA p.L552P/p.L552P mutant activity in pompe disease patient derived fibroblasts at 20 uM using 4-methylunbelliferyl alpha-D-glucopyranoside as substrate preincubated for 4 days followed by substrate addition measured after 60 mi2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID243908Inhibitory activity against beta-Glucosidase from Caldocellum saccharolyticum at 1000 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID579823Inhibition of endoplasmic reticulum alpha-glucosidase 2 in human HL-60 cells assessed as free oligosaccharide level at 50 uM after 24 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.
AID386383Inhibition of conduritol beta-epoxide-sensitive glucosylceramidase in C57BL/6 mouse testis membrane assessed as enzyme activity2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID579824Inhibition of rat liver alpha-glucosidase 2 assessed as conversion of Glc2Man7GlcNAc2 to Glc1Man7GlcNAc2 at 100 uM after 1.25 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.
AID104771Concentration giving 50% inhibition of growth of mock-infected MT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386365Effect on glucosylceramide level in C57BL/6 mouse testes2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID711092Inhibition of bovine liver beta-glucosidase at 1000 uM2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1596603Inhibition of GCase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID579822Inhibition of endoplasmic reticulum alpha-glucosidase 1 in human HL-60 cells assessed as free oligosaccharide level at 50 uM after 24 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID240826Inhibitory activity against alpha-Glucosidase from rice2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID104668Inhibition of Glycosidases (maltase) in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method maltase1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID731127Induction of lysosomal alpha-glucosidase L552P mutant activity in fibroblasts derived from patient after 9 days relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID386377Increase in glucosylceramide level in GBA2 deficient C57BL/6-129S1 mouse germ cells at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID208985Inhibition of Sucrase in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1467931Inhibition of GBA1/GBA2 derived from human HL60 cells using 4-MU-Glc as substrate after 30 mins by fluorescence assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID731631Induction of lysosomal alpha-glucosidase Y455F/Y455F mutant activity in fibroblasts derived from GSD type 2 patient relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID386380Decrease in testicular very long chain polyunsaturated fatty acid sphingomyelin level in beta-glucosidase 2 deficient C57BL/6-129S1 mouse at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID241803Inhibition of rat intestinal isomaltase using disaccharide2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID36810Competitive Inhibitory activity against Endoplasmic reticulum Alpha-Glucosidase II1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1467940Inhibition of rat liver lysosomal alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate by colorimetric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID105269Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MOLT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1467933Inhibition of recombinant human GAA by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID711103Inhibition of rat intestinal isomaltase using isomaltase as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID482220Cytotoxicity against human fibroblast at 300 uM after 24 hrs by MTT assay2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease.
AID553255Inhibition of sucrase in mouse intestinal input by glucose release assay2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.
AID386364Increase in neutral glycolipids level in C57BL/6 mouse testes2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID556068Antiviral activity against Bovine viral diarrhea virus 12009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses.
AID52058Inhibition of Cellobiase in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID386362Increase in complex glycosylated sphingolipids in C57BL/6 mouse testes at 5 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID731126Induction of lysosomal alpha-glucosidase G549R mutant activity in fibroblasts derived from patient after 9 days relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID36808Inhibition of endoplasmic reticulum Alpha-Glucosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID386382Inhibition mouse glucosylceramide synthase2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID466671Inhibition of GBA2 by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID386373Increase in long and saturated glucosylceramide level in C57BL/6 mouse testes at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1166038Inhibition of GBA1 (unknown origin) using beta-D-[1-14C]glucocerebroside assessed as 4-methylumbelliferrone by fluorimetry2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.
AID386378Effect on testicular ceramides level in C57BL/6 mouse at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID35368Competitive Inhibitory activity against Golgi Alpha-mannosidase II1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID386381Inhibition of conduritol beta-epoxide-sensitive mouse glucosylceramidase2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID711095Inhibition of porcine kidney trehalase2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID466853Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as reduction in blood insulin at 100 mg/kg/day for 4 weeks2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1895995Antiviral activity against DENV New Guinea C strain infected in African green monkey Vero cells assessed as reduction in viral infection measured after 5 days by plaque assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity.
AID466669Inhibition of lactase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID91639Inhibition of Glycosidases (isomaltase)in rat intestinal brush border membranes by D-glucose oxidase-peroxidase method1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1596608Anti-inflammatory activity in human CuFi1 cells assessed as reduction in Pseudomonas aeruginosa PAO1-induced IL-8 mRNA expression level pretreated for 1 hr followed by Pseudomonas aeruginosa PAO1 challenge and measured after 4 hrs by RT-PCR analysis2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID553254Inhibition of recombinant GBA2 preincubated with compound for 30 mins using 4-methylumbelliferyl-B-glucoside substrate by fluorimetric assay2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.
AID553258Selectivity index, ratio of IC50 for recombinant GBA1 to IC50 for glucosylceramide synthase in mouse RAW cells2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.
AID386393Effect on spermatogenesis in NZW mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID553257Inhibition of maltase in mouse intestinal input by glucose release assay2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.
AID386399Effect on complex glycosylated sphingolipids level in C57BL/6 mouse testes at 15 to 50 mg/kg/day, po2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1467920Inhibition of GBA1/GBA2 derived from human HL60 cells assessed as residual activity at 1 mM using 4-MU-Glc as substrate after 30 mins by fluorescence assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID386363Increase in complex glycosylated sphingolipids level in C57BL/6 mouse testes at 15 mg/kg/day administered with chow after 6 to 9 months2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID553253Inhibition of recombinant GBA1 preincubated with compound for 30 mins using 4-methylumbelliferyl-B-glucoside substrate by fluorimetric assay2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.
AID711098Inhibition of rat intestinal lactase using lactose as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID386366Effect on glucosylceramide level in C57BL/6 mouse testes at 15 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1460459Inhibition of endoplasmic reticulum alpha-glucosidase in HEK293 cells infected with DENV assessed as reduction in viral infection2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.
AID243763Inhibitory activity against alpha-Glucosidase from Yeast at 1000 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386371Increase in glucosylceramide level in C57BL/6 mouse testes administered with chow after 5 days2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1467932Inhibition of recombinant human GBA12017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID466666Inhibition of GCS by cell-based assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID35262Inhibition of golgi Alpha-mannosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID437997Inhibition of Saccharomyces cerevisiae alpha glucosidase2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.
AID553252Inhibition of glucosylceramide synthase in mouse RAW cells preincubated with compound for 15 mins by in-situ enzyme inhibition assay2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.
AID1884450Inhibition of human GCase assessed as reduction of 4-methylumbelliferone liberation using 4-methylumbelliferyl-beta-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition by fluorescence spectrophotometry2022European journal of medicinal chemistry, Aug-05, Volume: 238trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1467938Allosteric enhancement of GAA p.R375L/p.V755SfsX41 mutant activity in pompe disease patient derived fibroblasts at 20 uM using 4-methylunbelliferyl alpha-D-glucopyranoside as substrate preincubated for 4 days followed by substrate addition measured after 2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID386394Effect on spermatogenesis in DBA2 mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID386386Drug level in C57BL/6 mouse serum at 15 mg/kg/day assessed as enzyme activity2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID497872Inhibition of wild type Bacteroides thetaiotaomicron beta-mannosidase 2A expressed in Escherichia coli BL21 (DE3) at 37 degC and Ph 5.6 by 2,4-dinitrophenolate release assay2008Nature chemical biology, May, Volume: 4, Issue:5
Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
AID466854Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as increase in glucose tolerance at 100 mg/kg/day for 4 weeks by OGTT2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1596605Inhibition of NLGase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID553256Inhibition of lactase in mouse intestinal input by glucose release assay2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.
AID386388Effect on spermatogenesis in C57BL/6 mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID241706Inhibition of rat intestinal sucrase using disaccharide2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID386376Increase in glucosylceramide level in GBA2 deficient C57BL/6-129S1 mouse somatic cells at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID350169Inhibition of human placental beta-glucocerebrosidase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1596609Anti-inflammatory activity in human CuFi1 cells assessed as reduction in Pseudomonas aeruginosa PAO1-induced IL-8 mRNA expression level pretreated for 1 hr followed by Pseudomonas aeruginosa PAO1 challenge and measured after 4 hrs by RT-PCR analysis relat2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID556069Antiviral activity against Dengue virus2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses.
AID437994Inhibition of human GBA22009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.
AID35370Inhibition of soluble Alpha-mannosidase II in rat liver1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID243715Inhibitory activity against trehalase from porcine kidney at 1000 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
AID699203Inhibition of GCS assessed as amount of UDP glucose after 3 hrs by Fluorometry analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery and characterization of an inhibitor of glucosylceramide synthase.
AID437998Inhibition of Bacillus stearothermophilus alpha glucosidase2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.
AID1467914Inhibition of rice alpha-glucosidase assessed as residual activity at 1 mM using 4-Np-alpha-Glc as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID1596622Toxicity in Pseudomonas aeruginosa PAO1 infected C57Bl/6NCr mouse assessed as change in body weight at 10 to 100 mg/kg, po administered via gavage pretreated for 1 to 24 hrs followed by Pseudomonas aeruginosa PAO1 challenge and measured after 6 hrs2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID1895996Antiviral activity against SARS-CoV-2 England/2/2022 assessed as reduction in viral infection2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity.
AID466673Inhibition of glycogen glycogen de-branching enzyme by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID711104Inhibition of rat intestinal maltase using moltose as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID386367Increase in glucosylceramide level in C57BL/6 mouse testes at 300 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1467935Allosteric enhancement of GAA p.L552P/p.L552P mutant activity in pompe disease patient derived fibroblasts at 20 uM using 4-methylunbelliferyl alpha-D-glucopyranoside as substrate preincubated for 4 days followed by substrate addition measured after 60 mi2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID1596604Inhibition of GCase in human SH-SY5Y cells at 1 nM to 1 mM using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay relative to2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID386384Inhibition of conduritol beta-epoxide-sensitive glucosylceramidase in C57BL/6 mouse brain membrane assessed as enzyme activity2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID105266Concentration giving 50% inhibition of growth of mock-infected MOLT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID386368Increase in glucosylceramide level in C57BL/6 mouse spleen administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID437995Inhibition of human lysosomal alpha glucosidase2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors.
AID386361Reduction of complex glycosylated sphingolipids level in C57BL/6 mouse testes at 2400 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID466855Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as insulin resistance at 100 mg/kg/day for 4 weeks by HOMA-IR analysis2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1467937Allosteric enhancement of GAA aberrant splicing/unknown mutant activity in pompe disease patient derived fibroblasts at 20 uM using 4-methylunbelliferyl alpha-D-glucopyranoside as substrate preincubated for 4 days followed by substrate addition measured a2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1467922Inhibition of beta-hexosaminidase derived from human HL60 cells assessed as residual activity at 1 mM using 4-MU-GlcNAc as substrate after 30 mins by fluorescence assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1166039Inhibition of GBA2 (unknown origin)2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.
AID386379Effect on testicular sphingomyelin level in C57BL/6 mouse at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1467927Inhibition of Sulfolobus solfataricus alpha fucosidase assessed as residual activity at 1 mM using 4 Np-alpha-Fuc as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID731128Induction of lysosomal alpha-glucosidase P545L/P545L mutant activity in fibroblasts derived from GSD type 2 patient relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID700852Inhibition of non-lysosomal glucosylceramidase2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID350168Activation of beta-glucocerebrosidase N370S mutant in Goucher lymphoblasts cocultured with HL60 cells at 50 uM after 3 days relative to control2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
AID617701Inhibition of rat liver Alpha-glucosidase II2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Synthesis and α-Glucosidase II inhibitory activity of valienamine pseudodisaccharides relevant to N-glycan biosynthesis.
AID1467925Inhibition of Alicyclobacillus acidocaldarius beta-galactosidase assessed as residual activity at 1 mM using 2 Np-beta-Gal as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID711094Inhibition of rat intestinal cellobiase using cellobiose as substrate at 1000 uM2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1596612Cytotoxicity against human CuFi1 cells assessed as reduction in cell viability incubated for 48 hrs by Muse cell analyser method2019European journal of medicinal chemistry, Aug-01, Volume: 175Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
AID386391Effect on spermatogenesis in AKR mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID466852Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as reduction in blood glucose at 100 mg/kg/day for 4 weeks2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID386389Effect on spermatogenesis in C57BR mouse assessed as morphological changes in spermatozoa at 150 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID105142Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MT-4 cells1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication.
AID1467917Inhibition of wild type C57BL/6 mouse small intestinal lactase assessed as residual activity at 1 mM using lactose as substrate after 30 mins2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID652573Inhibition of glucosylceramidase 2 from spleen of patient with gaucher's disease by fluorimetric analysis2011ACS medicinal chemistry letters, Jul-14, Volume: 2, Issue:7
Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID466856Antidiabetic activity in obese, insulin resistant C57BL/6J mouse assessed as reduction in HbA1c at 100 mg/kg/day for 4 weeks2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1467919Inhibition of Sulfolobus solfataricus P2 beta-glucosidase assessed as residual activity at 1 mM using 4 Np-beta-Glc as substrate by UV-visible spectrophotometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
AID386397Effect on spermatogenesis in FVB/N mouse assessed as morphological changes in spermatozoa at 15 mg/kg/day administered with chow2007The Journal of biological chemistry, Nov-09, Volume: 282, Issue:45
Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.
AID1797728In Vitro Enzyme Inhibition from Article 10.1016/j.bmc.2006.08.003: \\Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.\\2006Bioorganic & medicinal chemistry, Dec-01, Volume: 14, Issue:23
Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
AID1799390Btman2A from Article 10.1038/nchembio.81: \\Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.\\2008Nature chemical biology, May, Volume: 4, Issue:5
Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (370)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.54)18.7374
1990's35 (9.46)18.2507
2000's127 (34.32)29.6817
2010's164 (44.32)24.3611
2020's42 (11.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.90 (24.57)
Research Supply Index6.02 (2.92)
Research Growth Index6.20 (4.65)
Search Engine Demand Index85.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (7.31%)5.53%
Reviews58 (15.14%)6.00%
Case Studies43 (11.23%)4.05%
Observational8 (2.09%)0.25%
Other246 (64.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years With Late-onset Pompe Disease [NCT03911505]Phase 322 participants (Anticipated)Interventional2020-02-13Recruiting
Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover, Proof-of-mechanism Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Adult Patients With Cystic Fibrosis Homozygous for the F50 [NCT02325362]Phase 2/Phase 316 participants (Actual)Interventional2015-03-17Completed
Phase 2 Pharmacological Trial to Evaluate the Safety of Miglustat Administration in Subjects With Spastic Paraplegia 11 (TreatSPG11) [NCT04768166]Phase 210 participants (Actual)Interventional2021-06-15Completed
Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset GM2 Gangliosidosis: Single and Steady State Oral Doses [NCT00672022]Phase 310 participants (Anticipated)Interventional2004-07-31Completed
Evaluation of Combination Therapy With Miglustat and Enzyme Replacement Therapy on Gaucher Disease Type IIIB [NCT02520934]19 participants (Actual)Interventional2015-07-31Active, not recruiting
A Phase II Randomized Controlled Study of Miglustat in Adult and Juvenile Patients With Niemann-Pick Type C Disease [NCT00517153]Phase 229 participants (Actual)Interventional2002-01-31Completed
A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy [NCT02185651]Phase 12 participants (Actual)Interventional2016-10-31Terminated(stopped due to Participants not interested in enrolling.)
Application of Miglustat in Patients With Niemann-Pick Type C [NCT01760564]Phase 35 participants (Actual)Interventional2008-01-31Completed
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease [NCT04138277]Phase 3110 participants (Anticipated)Interventional2019-12-18Active, not recruiting
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disea [NCT02675465]Phase 1/Phase 232 participants (Anticipated)Interventional2016-01-31Active, not recruiting
Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind Placebo-controlled Study. [NCT00945347]Phase 210 participants (Anticipated)Interventional2009-07-31Completed
Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation [NCT00742092]Phase 211 participants (Actual)Interventional2008-08-31Completed
An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to < 18 Years [NCT04808505]Phase 336 participants (Anticipated)Interventional2023-07-18Recruiting
Open-label, Non Comparative, Multi-center Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Oral Miglustat as a Maintenance Therapy After a Switch From Enzyme Replacement Therapy in Adult Patients With Stable Type 1 Gaucher Disease [NCT00319046]Phase 342 participants (Actual)Interventional2006-02-01Completed
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible) [NCT00002079]Phase 20 participants InterventionalCompleted
A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/Placebo [NCT03729362]Phase 3125 participants (Actual)Interventional2018-12-04Completed
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study [NCT00194649]Phase 48 participants (Actual)Interventional2005-06-30Completed
Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation [NCT00537602]Phase 26 participants (Actual)Interventional2007-11-30Terminated(stopped due to Methodology applied did not meet all criteria required per guidelines)
Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy [NCT01451879]11 participants (Actual)Observational2008-10-31Completed
A Phase I/II Randomized, Controlled Study of OGT 918 in Adult and Juvenile Patients With Niemann Pick C Disease [NCT00316498]Phase 130 participants Interventional2002-10-17Completed
A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease [NCT00041535]Phase 230 participants Interventional2002-07-05Completed
Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis: Single and Multiple Oral Doses [NCT00418847]Phase 25 participants (Actual)Interventional2004-07-31Completed
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3 [NCT00001993]Phase 2120 participants InterventionalCompleted
A Single-center, Double-blind, Randomized, Placebo-controlled, Two Period / Two Treatment Cross-over Study to Assess the Effect of Florastor® (Saccharomyces Boulardii Lyo) on Gastrointestinal Tolerability, Safety, and Pharmacokinetics of Zavesca® (Miglust [NCT01822028]Phase 142 participants (Actual)Interventional2013-03-31Completed
Survey of Miglustat Therapeutic Effects on Neurological and Systemic Symptoms of Infantile Type of Sandhoff and Taysachs Diseases [NCT03822013]Phase 330 participants (Anticipated)Interventional2019-01-14Recruiting
Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G) [NCT02030015]Phase 416 participants (Actual)Interventional2015-12-22Terminated(stopped due to Efficacy)
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex [NCT00000692]Phase 148 participants InterventionalCompleted
A Global Prospective Observational Registry of Patients With Pompe Disease [NCT06121011]500 participants (Anticipated)Observational [Patient Registry]2023-11-20Not yet recruiting
An Open-label Safety, Pharmacokinetic, and Efficacy Study of the Combination of Miglustat for the Treatment of CLN3 Disease in Patients 17 Years of Age and Older [NCT05174039]Phase 1/Phase 26 participants (Actual)Interventional2022-02-02Active, not recruiting
A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects [NCT03910621]Phase 417 participants (Actual)Interventional2020-04-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00319046 (4) [back to overview]Mean Percent Change From Baseline in Spleen Volume
NCT00319046 (4) [back to overview]Mean Within-patient Percent Change From Baseline in Liver Volume
NCT00319046 (4) [back to overview]Liver Volume at Baseline and at End of Treatment
NCT00319046 (4) [back to overview]Spleen Volume at Baseline and End of Treatment
NCT03729362 (33) [back to overview]Change From Baseline to Week 26 in 6MWD
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in % Predicted 6MWD
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in 6 Minute Walk Distance (6MWD)
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in European Quality of Life-5 Dimensions 5 Response Levels (EQ-5D-5L) Based on the EuroQol Visual Analogue Scale (EQ VAS) Quantitative Score
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Maximal Expiratory Pressure (MEP) % Predicted
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Maximal Inspiratory Pressure (MIP) % Predicted
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Maximum Vital Capacity (Maximum VC) % Predicted
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Rasch-Built Pompe-Specific Activity (R-PAct) Total Score
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Serum Creatine Kinase (CK) Level
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Sitting Forced Vital Capacity (FVC; % Predicted)
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Sitting Slow Vital Capacity (SVC) % Predicted
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Sniff Nasal Inspiratory Pressure (SNIP) % Predicted
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in the Manual Muscle Test (MMT) Score for the Lower Extremities
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in the Total Score for the Gait, Stairs, Gowers' Maneuver, and Chair (GSGC)
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in the Total Score for the Patient- Reported Outcomes Measurement Information System (PROMIS®) - Physical Function
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in the Total Score for the PROMIS® - Fatigue
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Urinary Hexose Tetrasaccharide (Hex4) Level
NCT03729362 (33) [back to overview]Noncompartmental Analysis: AUC From Time 0 (Predose) to the Time of Last Quantifiable Concentration of Plasma Total GAA Protein by Signature Peptide T09 in ERT-Naïve Subjects
NCT03729362 (33) [back to overview]Noncompartmental Analysis: Cmax of Plasma Total GAA Protein by Signature Peptide T09 in ERT-Naïve Subjects
NCT03729362 (33) [back to overview]Number of Participants Improving on Both 6MWD and % Predicted FVC at Week 52
NCT03729362 (33) [back to overview]Change From Baseline in the Time to Complete Individual GSGC Component Tests and Timed Up and Go (TUG) Test at Week 52
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in Other MMT Scores
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in PROMIS-Dyspnea and Upper Extremities Total Scores
NCT03729362 (33) [back to overview]Change From Baseline to Week 52 in the Quantitative Muscle Test (QMT) Values
NCT03729362 (33) [back to overview]Comparison of AUC of Cipaglucosidase Alfa in ERT- Experienced and ERT-Naïve Populations
NCT03729362 (33) [back to overview]Comparison of Cmax of Cipaglucosidase Alfa in ERT-Experienced and ERT-Naïve Populations
NCT03729362 (33) [back to overview]Number of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs)
NCT03729362 (33) [back to overview]Physician's Global Impression of Change (PGIC) Overall Status at Week 52
NCT03729362 (33) [back to overview]Population Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Experienced Participants Using Plasma Total GAA Protein Level by Signature Peptide Assay and Plasma Miglustat Concentration
NCT03729362 (33) [back to overview]Population PK: Area Under the Concentration-Time Curve (AUC) of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Experienced Participants Using Plasma Total GAA Protein Level by Signature Peptide Assay and Plasma Miglustat Concentration
NCT03729362 (33) [back to overview]Population PK: AUC of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Naïve Subjects
NCT03729362 (33) [back to overview]Population PK: Cmax of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Naïve Participants
NCT03729362 (33) [back to overview]Subject's Global Impression of Change (SGIC) at Week 52

Mean Percent Change From Baseline in Spleen Volume

"Spleen volume was assessed at baseline and end of treatment by magnetic resonance imaging.~Imputation methods for patients with missing values at Month 24 were applied as follows: if a patient had at least 640 days of treatment with the study drug, the last observation that was not more than 2 days after the end of treatment was carried forward. If a patient had discontinued study drug before Day 640, the 'worst' within-patient value not more than 2 days after the end of treatment was used to impute the missing value." (NCT00319046)
Timeframe: End of treatment (Month 24)

InterventionPercentage change (Mean)
Miglustat21.1

[back to top]

Mean Within-patient Percent Change From Baseline in Liver Volume

Liver volume was assessed at baseline and end of treatment by magnetic resonance imaging. Imputation methods for patients with missing values at Month 24 were applied as follows: if a patient had at least 640 days of treatment with the study drug, the last observation that was not more than 2 days after the end of treatment was carried forward. If a patient had discontinued study drug before Day 640, the 'worst' within-patient value not more than 2 days after the end of treatment was used to impute the missing value. (NCT00319046)
Timeframe: End of treatment (Month 24)

InterventionPercentage change (Mean)
Miglustat-1.1

[back to top]

Liver Volume at Baseline and at End of Treatment

Liver volume was assessed at baseline and end of treatment by magnetic resonance imaging. Imputation methods for patients with missing values at Month 24 were applied as follows: if a patient had at least 640 days of treatment with the study drug, the last observation that was not more than 2 days after the end of treatment was carried forward. If a patient had discontinued study drug before Day 640, the 'worst' within-patient value not more than 2 days after the end of treatment was used to impute the missing value. (NCT00319046)
Timeframe: Baseline and end of treatment (Month 24)

Interventioncm^3 (Mean)
BaselineEnd of treatment
Miglustat1774.61727.1

[back to top]

Spleen Volume at Baseline and End of Treatment

"Spleen volume was assessed at baseline and end of treatment by magnetic resonance imaging.~Imputation methods for patients with missing values at Month 24 were applied as follows: if a patient had at least 640 days of treatment with the study drug, the last observation that was not more than 2 days after the end of treatment was carried forward. If a patient had discontinued study drug before Day 640, the 'worst' within-patient value not more than 2 days after the end of treatment was used to impute the missing value." (NCT00319046)
Timeframe: Baseline and end of treatment (Month 24)

Interventioncm^3 (Mean)
BaselineEnd of treatment
Miglustat509.8611.9

[back to top]

Change From Baseline to Week 26 in 6MWD

The 6MWD, measured in meters, is the distance walked on the 6MWT. (NCT03729362)
Timeframe: Baseline, Week 26

Interventionmeter (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat16.45
Alglucosidase Alfa/Placebo8.28

[back to top]

Change From Baseline to Week 52 in % Predicted 6MWD

The % predicted 6MWD = (actual 6MWD / predicted 6MWD) * 100. The predicted values were calculated using Enright And Sherrill 1998 Reference Equations. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionpercentage of predicted 6MWD (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat4.039
Alglucosidase Alfa/Placebo1.655

[back to top]

Change From Baseline to Week 52 in 6 Minute Walk Distance (6MWD)

The efficacy of cipaglucosidase alfa/miglustat co-administration on ambulatory function was measured by the 6MWT. The 6MWD, measured in meters, is the distance walked on the 6MWT. A greater distance indicated greater endurance. An increase from baseline indicated improvement. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionmeter (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat21.31
Alglucosidase Alfa/Placebo7.10

[back to top]

Change From Baseline to Week 52 in European Quality of Life-5 Dimensions 5 Response Levels (EQ-5D-5L) Based on the EuroQol Visual Analogue Scale (EQ VAS) Quantitative Score

The EuroQol Visual Analogue Scale (EQ VAS) is a vertical visual analogue scale that records the respondent's own assessment of his or her overall health status at the time of completion. Scores range from 0 (the worst health you can imagine) to 100 (the best health you can imagine). Higher EQ VAS scores represent an improved sense of overall health while lower scores represent a worsening of overall health. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat0.03
Alglucosidase Alfa/Placebo3.61

[back to top]

Change From Baseline to Week 52 in Maximal Expiratory Pressure (MEP) % Predicted

"The percent predicted values of MEP were calculated as: % predicted = (actual result / predicted result)~* 100, where the predicted results were obtained using the reference equations from Uldry and Fitting (1995)." (NCT03729362)
Timeframe: Baseline, Week 52

Interventionpercentage of predicted MEP (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat0.51
Alglucosidase Alfa/Placebo-1.35

[back to top]

Change From Baseline to Week 52 in Maximal Inspiratory Pressure (MIP) % Predicted

The percent predicted values of MIP were calculated as: % predicted = (actual result / predicted result)* 100, where the predicted results were obtained using the reference equations from Uldry and Fitting (1995). (NCT03729362)
Timeframe: Baseline, Week 52

Interventionpercentage of predicted MIP (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat1.89
Alglucosidase Alfa/Placebo-2.31

[back to top]

Change From Baseline to Week 52 in Maximum Vital Capacity (Maximum VC) % Predicted

Maximum VC is the greater of the two VC values (FVC or SVC). (NCT03729362)
Timeframe: Baseline, Week 52

Interventionpercentage of predicted maximum VC (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat-1.286
Alglucosidase Alfa/Placebo-3.695

[back to top]

Change From Baseline to Week 52 in Rasch-Built Pompe-Specific Activity (R-PAct) Total Score

The R-PAct scale was an 18-item questionnaire to measure limitations in activities and restriction in social participation. Possible responses to questions were as follows: unable to perform, able to perform, but with difficulty, and able to perform without difficulty. The total score was calculated by summing up the observed scores across the 18 items and it ranged from 0 to 36, with higher values representing lower level of disease impact on the muscles. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat0.04
Alglucosidase Alfa/Placebo0.51

[back to top]

Change From Baseline to Week 52 in Serum Creatine Kinase (CK) Level

Change from baseline to Week 52 in serum CK level. CK levels were measured as part of the serum chemistry panel. (NCT03729362)
Timeframe: Baseline, Week 52

InterventionU/L (Mean)
Cipaglucosidase Alfa/Miglustat-130.5
Alglucosidase Alfa/Placebo60.2

[back to top]

Change From Baseline to Week 52 in Sitting Forced Vital Capacity (FVC; % Predicted)

The efficacy of cipaglucosidase alfa/miglustat co-administration on pulmonary function was measured by sitting FVC (% predicted). FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionpercentage of predicted FVC (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat-1.04
Alglucosidase Alfa/Placebo-3.70

[back to top]

Change From Baseline to Week 52 in Sitting Slow Vital Capacity (SVC) % Predicted

SVC is a standard pulmonary function test used to quantify respiratory muscle weakness. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionpercentage of predicted SVC (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat-2.527
Alglucosidase Alfa/Placebo-5.368

[back to top]

Change From Baseline to Week 52 in Sniff Nasal Inspiratory Pressure (SNIP) % Predicted

The percent predicted values of SNIP were calculated as: % predicted = (actual result / predicted result) * 100, where the predicted results were obtained using the reference equations from Evans and Whitelaw (2009). (NCT03729362)
Timeframe: Baseline, Week 52

Interventionpercentage of predicted SNIP (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat1.40
Alglucosidase Alfa/Placebo4.53

[back to top]

Change From Baseline to Week 52 in the Manual Muscle Test (MMT) Score for the Lower Extremities

The total score for the MMT lower extremity strength included the following 8 body parts: right/left hip flexion, right/left hip abduction, right/left knee flexion and right/left knee extension. The MMT lower extremity score ranged from 0 to 40, with lower scores indicating weaker muscle strength. An increase from baseline indicated increased muscle strength. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat1.64
Alglucosidase Alfa/Placebo0.68

[back to top]

Change From Baseline to Week 52 in the Total Score for the Gait, Stairs, Gowers' Maneuver, and Chair (GSGC)

The GSGC consisted of a 10-meter walk for evaluation of gait, a 4-stair climb, Gowers' maneuver, and arising from a chair. Results of the GSGC included the time required to complete the individual tests, individual scores for each of the tests (1 to 7 points for each of gait, 4-stair climb, and Gowers' maneuver, and 1 to 6 points for arising from a chair), and a total score. GSGC total score was the sum of the component scores from the 4 functional tests. The total score ranged from a minimum of 4 points (normal performance) to a maximum of 27 points (worst performance). (NCT03729362)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat-0.567
Alglucosidase Alfa/Placebo0.847

[back to top]

Change From Baseline to Week 52 in the Total Score for the Patient- Reported Outcomes Measurement Information System (PROMIS®) - Physical Function

Physical Function Short Form 20a (v2.0) consisted of 20 questions. The first 14 questions were each scored on a scale from 1 to 5 as follows: 1 = unable to do; 2 = with much difficulty; 3 = with some difficulty; 4 = with a little difficulty; 5 = without any difficulty; the next 6 questions were each scored on a scale from 1 to 5 as follows: 1 = cannot do; 2 = quite a lot; 3 = somewhat; 4 = very little; 5 = not at all. The total score was calculated by summing up scores (1 to 5) across all items. Total scores range from 20 to 100. A higher score represented a better outcome. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat1.98
Alglucosidase Alfa/Placebo0.11

[back to top]

Change From Baseline to Week 52 in the Total Score for the PROMIS® - Fatigue

Fatigue Short Form 8a consisted of 6 questions, each scored on a scale from 1 to 5 as follows: 1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; 5 = very much; and 2 questions, each scored on a scale from 1 to 5 as follows: 1 = never; 2 = rarely; 3 = sometimes; 4 = often; 5 = always. The total score was calculated by summing up scores (1 to 5) across all items. A lower score represented lower fatigue symptoms. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Cipaglucosidase Alfa/Miglustat-1.90
Alglucosidase Alfa/Placebo-1.94

[back to top]

Change From Baseline to Week 52 in Urinary Hexose Tetrasaccharide (Hex4) Level

Levels of urinary Hex4, a biomarker of disease substrate, were measured. The assay specifically targets Hex4, the glucose tetrasaccharide (Glc4), which is a biomarker of glycogen storage. (NCT03729362)
Timeframe: Baseline, Week 52

Interventionmmol/mol creatinine (Mean)
Cipaglucosidase Alfa/Miglustat-1.88
Alglucosidase Alfa/Placebo1.22

[back to top]

Noncompartmental Analysis: AUC From Time 0 (Predose) to the Time of Last Quantifiable Concentration of Plasma Total GAA Protein by Signature Peptide T09 in ERT-Naïve Subjects

A noncompartmental analysis was performed on ERT-naïve subjects, who underwent serial PK sampling during the study. On Day 1, serial blood samples were collected for ERT-naïve participants just prior to initiation of cipaglucosidase alfa/alglucosidase alfa infusion (time 0) and at 1, 2, 3, 3.5, 4, 4.5, 6, 8, 10, and 24 hours after the start of cipaglucosidase alfa/alglucosidase alfa infusion for plasma total GAA protein signature peptide T09 and plasma miglustat determinations. (NCT03729362)
Timeframe: Day 1

Interventionμg·h/mL (Geometric Mean)
Cipaglucosidase Alfa1264
Alglucosidase Alfa1656
Miglustat20588

[back to top]

Noncompartmental Analysis: Cmax of Plasma Total GAA Protein by Signature Peptide T09 in ERT-Naïve Subjects

A noncompartmental analysis was performed on ERT-naïve subjects, who underwent serial PK sampling during the study. On Day 1, serial blood samples were collected for ERT-naïve participants just prior to initiation of cipaglucosidase alfa/alglucosidase alfa infusion (time 0) and at 1, 2, 3, 3.5, 4, 4.5, 6, 8, 10, and 24 hours after the start of cipaglucosidase alfa/alglucosidase alfa infusion for plasma total human acid α-glucosidase (GAA) protein signature peptide T09 and plasma miglustat determinations. (NCT03729362)
Timeframe: Day 1

Interventionμg/mL (Geometric Mean)
Cipaglucosidase Alfa260
Alglucosidase Alfa364
Miglustat2768

[back to top]

Number of Participants Improving on Both 6MWD and % Predicted FVC at Week 52

A composite subject-level response of the 2 relevant clinical outcomes, 6MWD and FVC (% predicted), was assessed. Prespecified thresholds were used for assessment of improvement consistent with published minimal clinically important difference values for comparable instruments in similar disease. (NCT03729362)
Timeframe: Week 52

InterventionParticipants (Number)
Cipaglucosidase Alfa/Miglustat14
Alglucosidase Alfa/Placebo0

[back to top]

Change From Baseline in the Time to Complete Individual GSGC Component Tests and Timed Up and Go (TUG) Test at Week 52

Motor function test assessed the time to complete individual GSGC component tests (10-meter walk, 4- stair climb, Gowers' maneuver, and arise from a chair) and the TUG test. The TUG test assessed the time a subject needed to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. (NCT03729362)
Timeframe: Baseline, Week 52

,
Interventionseconds (Least Squares Mean)
Time to complete the 10-meter walkTime to complete the 4-stair climbTime to complete the Gowers' maneuverTime to arise from a chairTime to complete the timed up and go test
Alglucosidase Alfa/Placebo2.06-3.61-1.95-6.750.09
Cipaglucosidase Alfa/Miglustat-0.60-6.75-0.36-7.57-0.39

[back to top]

Change From Baseline to Week 52 in Other MMT Scores

"Each manual muscle test was evaluated on a scoring scale from 0 to 5, as follows: 0 = no muscle movement; 1 = visible muscle movement, but no movement at the joint; 2 = movement at the joint, but not against gravity; 3 = movement against gravity, but not against added resistance; 4 = movement against resistance, but less than normal; 5 = normal strength. Upper extremity score was the sum of scores for right/left shoulder abduction, right/left shoulder adduction, right/left elbow extension, and right/left elbow flexion, with the total score ranging from 0 to 40.~Proximal muscle group score, the sum of scores for right/left hip flexion, right/left hip abduction, right/left shoulder abduction, and right/left shoulder adduction, with the total score ranging from 0 to 40. MMT total score was the sum of the lower and upper extremity scores and ranged from 0 to 80. Lower scores indicated lower overall muscle strength. An increase from baseline indicated improvement in muscle strength." (NCT03729362)
Timeframe: Baseline, Week 52

,
Interventionscore on a scale (Least Squares Mean)
MMT Upper Extremity ScoreMMT Total ScoreMMT Proximal Muscle Group Score
Alglucosidase Alfa/Placebo0.601.020.70
Cipaglucosidase Alfa/Miglustat1.543.241.82

[back to top]

Change From Baseline to Week 52 in PROMIS-Dyspnea and Upper Extremities Total Scores

"The Upper Extremities Short Form 7a consisted of 7 items each scored on a decreasing scale from 1 to 5 as follows: 1 = unable to do; 2 = with much difficulty; 3 = with some difficulty; 4 = with a little difficulty; 5 = without any difficulty.~Dyspnea Severity Short Form 10a consisted of 10 items each scored on a scale from 0 to 3 as follows: 0~= no shortness of breath; 1 = mildly short of breath; 2 = moderately short of breath; 3 = severely short of breath.~A total score was generated for each instrument by adding up each item. Total scores for upper extremities range from 7 to 35. Total scores for dyspnea range from 0 to 30. A higher score for upper extremities represented improvement in symptoms. A lower score for dyspnea severity represented improvement in symptoms." (NCT03729362)
Timeframe: Baseline, Week 52

,
Interventionscore on a scale (Least Squares Mean)
PROMIS-Dyspnea Total ScorePROMIS-Upper Extremities Total Score
Alglucosidase Alfa/Placebo-1.500.87
Cipaglucosidase Alfa/Miglustat-0.410.97

[back to top]

Change From Baseline to Week 52 in the Quantitative Muscle Test (QMT) Values

QMT was measured using the hand-held dynamometer. Larger values (in kg) indicated greater muscle strength. (NCT03729362)
Timeframe: Baseline, Week 52

,
Interventionkilogram (Least Squares Mean)
QMT Value for the Upper ExtremitiesQMT Value for the Lower ExtremitiesQMT Total ValueQMT Value for the Proximal Muscle Group
Alglucosidase Alfa/Placebo-0.5535.2655.1980.945
Cipaglucosidase Alfa/Miglustat1.8396.4968.1953.401

[back to top]

Comparison of AUC of Cipaglucosidase Alfa in ERT- Experienced and ERT-Naïve Populations

On Days 1 and 364 (Week 52), sparse blood samples were collected for PK analysis at 0, 1, 4, 6, 12, and 24 hours post-dose. Collection of the 12-hour sample was optional. (NCT03729362)
Timeframe: Days 1 and 364 (Week 52)

,
Interventionμg·h/mL (Geometric Mean)
Day 1Day 364
Cipaglucosidase Alfa (ERT-experienced)13951476
Cipaglucosidase Alfa (ERT-naive)13431457

[back to top]

Comparison of Cmax of Cipaglucosidase Alfa in ERT-Experienced and ERT-Naïve Populations

On Days 1 and 364 (Week 52), sparse blood samples were collected for PK analysis at 0, 1, 4, 6, 12, and 24 hours post-dose. Collection of the 12-hour sample was optional. (NCT03729362)
Timeframe: Days 1 and 364 (Week 52)

,
Interventionμg/mL (Geometric Mean)
Day 1Day 364
Cipaglucosidase Alfa (ERT-experienced)280296
Cipaglucosidase Alfa (ERT-naive)273290

[back to top]

Number of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs)

Treatment-emergent ADAs were defined as participants who had seroconverted or boosted their preexisting ADA during the study period. (NCT03729362)
Timeframe: Baseline up to Week 52

,
Interventionparticipants (Number)
ERT-experienced: Treatment-emergent ADAsERT-naïve: Treatment-emergent ADAs
Alglucosidase Alfa/Placebo58
Cipaglucosidase Alfa/Miglustat3119

[back to top]

Physician's Global Impression of Change (PGIC) Overall Status at Week 52

"Physician's Global Impression of Change is based on a single item that is scored on a 7-point rating scale ranging from 1 very much worse to 7 very much improved.~A tertiary response variable (improving, declining, stable) was defined as follows: Improving, which consisted of improved, moderately improved, and very much improved; Declining, which consisted of worse, moderately worse, and very much worse; and Stable, which equaled to no change." (NCT03729362)
Timeframe: Week 52

,
InterventionParticipants (Number)
ImprovingStableDeclining
Alglucosidase Alfa/Placebo101610
Cipaglucosidase Alfa/Miglustat313811

[back to top]

Population Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Experienced Participants Using Plasma Total GAA Protein Level by Signature Peptide Assay and Plasma Miglustat Concentration

On Days 1 and 364 (Week 52), sparse blood samples were collected for PK analysis in ERT-experienced participants at 0, 1, 4, 6, 12, and 24 hours post-dose. Collection of the 12-hour sample was optional. (NCT03729362)
Timeframe: Days 1 and 364 (Week 52)

,
Interventionμg/mL (Geometric Mean)
Day 1Day 364
Alglucosidase Alfa/Placebo289283
Cipaglucosidase Alfa/Miglustat280293

[back to top]

Population PK: Area Under the Concentration-Time Curve (AUC) of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Experienced Participants Using Plasma Total GAA Protein Level by Signature Peptide Assay and Plasma Miglustat Concentration

On Days 1 and 364 (Week 52), sparse blood samples were collected for PK analysis in ERT-experienced participants at 0, 1, 4, 6, 12, and 24 hours post-dose. Collection of the 12-hour sample was optional. (NCT03729362)
Timeframe: Days 1 and 364 (Week 52)

,
Interventionμg·h/mL (Geometric Mean)
Day 1Day 364
Alglucosidase Alfa/Placebo17001688
Cipaglucosidase Alfa/Miglustat13951476

[back to top]

Population PK: AUC of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Naïve Subjects

On Days 1 and 364 (Week 52), sparse blood samples were collected for PK analysis in ERT-naïve participants at 0, 1, 4, 6, 12, and 24 hours post-dose. Collection of the 12-hour sample was optional. (NCT03729362)
Timeframe: Days 1 and 364 (Week 52)

,
Interventionμg·h/mL (Geometric Mean)
Day 1Day 364
Alglucosidase Alfa/Placebo18591964
Cipaglucosidase Alfa/Miglustat13431457

[back to top]

Population PK: Cmax of Cipaglucosidase Alfa and Alglucosidase Alfa in ERT-Naïve Participants

On Days 1 and 364 (Week 52), sparse blood samples were collected for PK analysis in ERT-naïve participants at 0, 1, 4, 6, 12, and 24 hours post-dose. Collection of the 12-hour sample was optional. (NCT03729362)
Timeframe: Days 1 and 364 (Week 52)

,
Interventionμg/mL (Geometric Mean)
Day 1Day 364
Alglucosidase Alfa/Placebo342359
Cipaglucosidase Alfa/Miglustat273290

[back to top]

Subject's Global Impression of Change (SGIC) at Week 52

"The SGIC is designed to record the participants' impression of their functional status since starting study drug using a 7-point scale ranging from 1 very much worse to 7 very much improved.~A tertiary response variable (improving, declining, stable) was defined as follows: Improving, which consisted of improved, moderately improved, and very much improved; Declining, which consisted of worse, moderately worse, and very much worse; and Stable, which equaled to no change." (NCT03729362)
Timeframe: Week 52

,
InterventionParticipants (Number)
ImprovingStableDeclining
Alglucosidase Alfa/Placebo131211
Cipaglucosidase Alfa/Miglustat363312

[back to top]